Quanterix Earnings Call Transcripts
Fiscal Year 2026
-
The company completed its Akoya integration, achieved $85 million in synergies, and restructured its commercial organization for deeper market focus. Diagnostics growth is driven by LucentAD Complete, with FDA approval and payer coverage progressing. Revenue is expected to improve in Q4, and cash flow breakeven is targeted for next year.
-
Q2 2026 revenue grew 34% as reported but fell 23% pro forma, prompting a guidance cut to $142–$148 million for the year. Leadership changes and commercial reorganization aim to address execution issues, while diagnostics, especially Alzheimer's testing, is a key growth focus with new insurance coverage and product launches.
-
The company is advancing its diagnostics strategy with a five-marker Alzheimer's test, aiming for FDA approval and strong payer support in the second half. Investments in commercial capabilities, innovation, and leadership are expected to drive growth and margin expansion, with cash flow breakeven targeted by year-end.
-
Q1 2026 revenue grew 20% year-over-year to $36.4 million, with strong diagnostics partner growth but declines in core segments. Strategic investments in commercial effectiveness and diagnostics are expected to drive a stronger second half, with cash flow breakeven targeted by year-end.
-
New leadership is driving a strategic transformation, emphasizing diagnostics as a growth engine and leveraging the Akoya acquisition for diversification. Financial discipline has resulted in strong recurring revenue and margin recovery, while a differentiated diagnostics test and focused product development position the company for sustainable growth.
-
Management outlined a strategy focused on diagnostics growth, especially in Alzheimer's, leveraging a strong recurring revenue base and successful Akoya integration. Financial performance exceeded expectations, with robust consumables demand and margin improvements. A comprehensive diagnostics plan and further international expansion are key priorities for future growth.
Fiscal Year 2025
-
Q4 2025 revenue rose 25% year-over-year to $43.9 million, with strong academic demand and expanded diagnostics partnerships. 2026 guidance targets $169–$174 million revenue, cash flow breakeven in H2, and continued investment in Alzheimer's diagnostics and assay innovation.
-
Q3 revenue grew 12% year-over-year to $40.2 million, driven by strong integration progress and early cross-selling between Simoa and Spatial platforms. Despite academic and pharma market headwinds, cost synergies and R&D investments position the company for growth and profitability in 2026.
-
Guidance for 2025 anticipates a core business decline, but consumables and diagnostics show resilience. Integration with Akoya is progressing, with $85M in synergies targeted by 2026 and a focus on assay innovation, menu expansion, and new diagnostic launches.
-
Q2 revenue fell 29% year-over-year to $24.5 million amid academic and pharma funding headwinds, but cost actions and the Akoya acquisition position the company for long-term growth. Guidance for 2025 is $130–$135 million in revenue, with $85 million in synergy savings targeted.
-
Record consumables growth and strong Accelerator Lab performance highlight resilience amid academic and biopharma delays. Simoa One platform and Akoya acquisition are set to expand market reach, while Alzheimer’s diagnostics remain on track for FDA submission this year.
-
Q1 2025 revenue declined 5% YoY to $30.3M, but consumables hit a record high, offsetting softness in other segments. Revised 2025 guidance reflects macro headwinds, with cost reductions and strategic initiatives like Simoa ONE and the Akoya merger supporting a path to positive cash flow by 2026.
-
Strong operational execution and innovation have driven sustained double-digit growth, with new product launches and the upcoming Simoa One platform expanding market reach. The Akoya acquisition and advancements in Alzheimer's diagnostics position the company for accelerated growth and profitability in 2026.
-
The merger creates a market leader in integrated blood and tissue biomarker detection, targeting neurology, oncology, and immunology. Expected synergies of $40 million by 2026, strong double-digit revenue growth, and accelerated profitability are anticipated, with closing in Q2 2025.
Fiscal Year 2024
-
Q4 revenue grew 11% year-over-year to $35.2 million, with strong Accelerator Lab and recurring revenue performance. 2025 guidance anticipates 2–6% growth, with near-term headwinds from the U.S. academic market and a ramp expected in the second half. Merger with Akoya aims to expand addressable markets and accelerate profitability.
-
Q3 2024 revenue grew 13% year-over-year to $35.7 million, led by Accelerator Lab and consumables, while instrument sales declined. Guidance for 2024 is reaffirmed, with double-digit growth and strong liquidity supporting strategic expansion in neurology and diagnostics.
-
Simoa technology’s high sensitivity is driving clinical adoption, with strong growth despite macro headwinds. The company is launching 20 new assays in 2024, expanding into immunology and oncology, and advancing regulatory progress for its p-Tau 217 test. Gross margins and cash flow are improving, with continued investment in innovation and partnerships.
-
Double-digit growth continues, driven by strong service revenue and robust demand for high-sensitivity assays, while instrument sales remain flat. The company is launching 20 new assays in 2024, focusing on multiplex innovation and expanding partnerships with major hospital networks to support diagnostic adoption.
-
Q2 revenue grew 11% year-over-year to $34.4 million, led by strong accelerator lab and consumables growth, while instrument sales declined due to ongoing capital constraints. Updated 2024 guidance reflects continued instrument weakness but double-digit growth, with robust liquidity and expanding diagnostic partnerships.
-
Recent regulatory support for new Alzheimer's therapies is driving demand for blood-based diagnostics, with early detection and ongoing monitoring seen as key differentiators. Strong Q1 growth, improved margins, and innovation in multi-marker testing position the business for expansion, with FDA submission for p-Tau 217 targeted for late 2024.